"Effect.Measure.v.descriptive","PMID","First.Author","Published","Year.Published","Include.area","Study.Funding.source.s.","Possible.Conflict.of.interest.for.study.authors","Study.purpose","Study.type","Vaccine.type","Vaccine.strategy","Number.doses.MVA.BN","Subcutaneous.or.intradermal.MVA.BN","Intervention.status","Dates.of.Outbreak","Country.of.outbreak","Population.description","Inclusion.Criteria","Exclusion.Criteria","Total.cohort.size.or.close.contact.pool","Case.report.forms.Complete.information..n.","Total.Cases.in.case.control","Total.control.in.case.control","loss.to.follow.up","Total.number.vaccinated.people","Historic.smallpox","PEP.or...14.days.after.1.dose","..1.dose.MVA.BN.vaccine.or.partially.vaccinated","..2.dose.MVA.BN.vaccine.or.fully.vaccinated","Subcutaneous","Intradermal","heterologous","Total.number.unvaccinated.people","unknown.vaccine.status","Episodes.outbreaks","Total.mpox.Cases","Total.vaccinated.mpox.cases","Total.vaccinated.mpox.historic.1st.gen.cases","Total.vaccinated.mpox.historic.2nd.gen.cases","Total.vaccinated.mpox.PEP.cases","Total.vaccinated.mpox.non.PEP.1.dose.cases","Total.vaccinated.mpox.2.dose","Total.unvaccinated.mpox.cases","Total.vaccinated.mpox.controls","Total.unvaccinated.mpox.controls","Notes.N","Measure..HR..IRR..RR..cumulative.incidence..attack.rate.etc.","..95..CI...67","Effect.measure","Dose","Adjusted","VE.type","Sensitivity","VE.outcome","Lower.CI","Upper.CI","Central.Effect.Estimate.reported","Effect.Est.lower.95.CI","Effect.Est.upper.95.CI","Regression.Coefficient","Regression.Coefficient.lower.95..CI","Regression.Coefficient.upper.95..CI","Vaccinated.secondary.cases","Unvaccinated.secondary.cases","Vaccinated.Contacts","Unvaccinated.Contacts","Vaccinated.or.cases.event","n.vaccinated.or.cases","unvaccinated..or.controls.event","n.unvaccinated.or.controls","unknown.or.missing.event.vaccinated","unknown.or.missing.total.n","Person.days.vaccinated","events.vaccinated","Person.days.unvaccinated","events.unvaccinated","crude.VE","..95..CI...97","Mean.vaccinated","sd.vaccinated","Mean.unvaccinated","sd.unvaccinated","Median.vaccinated","Lower.IQR.vaccinated","Upper.IQR.vaccinated","Median.unvaccinated","Lower.IQR.unvaccinated","Upper.IQR.unvaccinated","Controlled.for","Timing.of.measure","Cohort.Age...median.or.description.","Cohort.IQR.Age.lower","Cohort.IQR.Age.higher","Cohort.age.mean","Cohort.age.sd","Cohort.vaccinated.age.median","Cohort.unvaccinated.age.median","Cohort.unvaccinated.age.IQR","Cohort.unvaccinated.age.mean","Cohort.unvaccinated.age.sd","Cohort.age.unvaccinated..median","Cohort.age.unvaccinated.IQR","Cohort.age.vaccinated..mean","Cohort.age.vaccinated.sd","Monkeypox.cases.Age...median.","Monkeypox.cases.IQR.Age.lower","Monkeypox.cases.IQR.Age.higher","Monkeypox.controls.Age...median.","Monkeypox.controls.IQR.Age.lower","Monkeypox.controls.IQR.Age.higher","Cohort.cis.male.n","vaccinated..Male.n","unvaccinated..Male.n","cohort.MSM.n","vaccinated..MSM.n","unvaccinated.MSM.n","Monkeypox.cases.vaccinated.MSM.n","Monkeypox.cases.unvaccinated.MSM.n","Monkeypox.cases.vaccinated.non.MSM.n","Monkeypox.cases.unvaccinated.non.MSM.n","n.Non.Hispanic.White","Hispanic.Latino.n","Black.n....presumed","n.Known.HIV.status","n.HIV.positive","n.HIV.positive.vaccinated","n.HIV.positive.unvaccinated","n.CD4..200","n.VL...200","n.VL..50","n.PrEP.users","n.PrEP.users.vaccinated","n.PrEP.users.unvaccinated","n.Known.Hospital.status","n.Hospitalized","n.Hospitalized.vaccinated","n.Hospitalized.unvaccinated","n.not.hospitalized.vaccinated","n.not.hospitalized.unvaccinated","Limitations","...682","Internal.notes.for.coding"
"1","35623380","Adler","Lancet Infectious Diseases",2022,"Severity","None","No","Describe longitudinal clinical course of monkeypox in high-income setting with viral dynamic and adverse effects to novel antivirals","retrospective case series","MVA-BN","PEP","1","Subcutaneous",NA,"Aug 15, 2018- Sept 10, 2021","UK","British population","positive mpox infection","N/A","7",7,NA,NA,NA,1,NA,NA,NA,NA,NA,NA,NA,6,NA,"1","7","1",NA,NA,NA,NA,NA,"6",NA,NA,NA,"OR",NA,NA,"1","N","1 dose MBA-BN PEP severity N lesions","N",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,32,NA,71.6,53.4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Ages only given by decade","Ages only given by decade",NA,NA,NA,"Ages only given by decade","Ages only given by decade",NA,NA,"Ages only given by decade","Ages only given by decade","Ages only given by decade",NA,NA,NA,NA,NA,"4","0",4,"0","0","0",NA,NA,NA,NA,NA,NA,NA,"6","0","0","0","0",0,"0","0","0","0","7","7","1","6","0","0","Observational study- small number, short time frame for follow-up. Also their was an inability to confirm positive PCR results with viral culture. This made it very difficult to determine if the individual was shedding the virus.",NA,NA
"8","36924787","Bertran","Lancet Inf Disease",2023,"Infection","UK Health Security Agency","None","""observational study which aimed to
estimate the effectiveness of one dose of MVA–BN
against symptomatic mpox in England.""","Case-coverage study","MVA-BN","PEP, vaccination prior to exposure","1","subcutaneous","Aggregated vaccination coverage reporting system from NHS England and self-completed questionnaire from confirmed and highly-probably cases","July 4 -Oct 9 2022","England","Gay or MSM in England","Cases with an index date July 4, 2022- Oct 9, 2022","Women, heterosexual men, and those with missing vaccination information were excluded.","363",363,NA,NA,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,"1","363",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"OR",95,"VE","1","N","1 dose MVA-BN","N","0.78","0.54","0.89",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"at least 14 days after 1st dose",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"25","37199451","Deputy","NEJM",2023,"Infection","CDC, Epic","Employment at Epic","Vaccine effectiveness","Case-Control","MVA-BN","PEP, vaccination prior to exposure","1, 2","both","Electronic health records vis Epic program Cosmos (>169 million patient records across the U.S.)","Aug 15- Nov 19, 2022","USA","Patients with an mpox diagnosis or positive Orthopoxvirus or mpox virus laboratory result from 8/15 - 11/19/2022 in all 50 states of the United States","Part of Epic EHR (serves > 169 million US patients): Case: any gender identity and age with initial mpox diagnosis code or positive Orthopoxvirus or MPXV laboratory test during study period; Controls incidence clinical HIV diagnosis or new positive HIV antigen/antibody test or new or refill of HIV PrEP with in-person clinic visit during study period","previous mpox diagnosis or positive Orthopoxvirus or MPXV laboratory test from August 15 2021 to August 14 2022, no in person medical encounters 3 years before index event, controls with prescription for tecovirimat 14 days before index event to end of study period, 2 vaccines given < 24 days apart, received 1 dose less than 14 days before index event","11232",11232,2193,8319,NA,1506,NA,NA,1146,360,69,47,158,10872,NA,"1","2193","86",NA,NA,NA,58,28,"223",415,193,NA,"OR",95,"VE","2","Y","2 dose MVA-BN","N","0.66","0.47399999999999998","0.78100000000000003",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"age, race/ethnicity, social vulnerability, immune compromised state",NA,"cases: 18-35 1252 (55.3%), 36-49 707 (31.2%), 50-64 273 (12%), >= 65 ; Controls 18-35 4,221(48.8%), 36-49 2,434 (28.1%), 50-64 1,619 (18.7%), >= 65 375 (4.3%)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"89.2% cases and 89.2% female",NA,NA,NA,NA,NA,NA,NA,NA,NA,"35% cases, 55.5% controls","22.1% cases, 17.6% controls","36% cases, 17.9% controls","37.9% cases, 16.3% controls","37.9% cases, 16.3% controls;",NA,NA,"9.4% with CD4<200 in cases and 2.9% in controls",NA,NA,"13.5% case, 100% controls in those without HIV infection",NA,NA,NA,NA,NA,NA,NA,NA,"small populations in small analysis, misclassification, under ascertainment",NA,NA
"33","37200229","Dalton","MMWR",2023,"Infection","CDC","Some study authors on safety monitoring boards of pharmaceutical companies, none for Bavarian Nordic","VE of full and partial vaccination MVA-Bn","Case-Control,","MVA-BN","vaccination prior to exposure","1,2","subcutaneous, intradermal, heterologous","vacciantion from state immunization registries","Aug 19, 2022 - March 31, 2023","USA","Sexually active MSM or transgender aged 18-49 in 12 U.S. jurisdictions","cases probable and confirmed mpox cases Mpox virus or Orthopoxvirus diagnosis on or after Aug 19,2022, controls, identified from healthcare setting providing HIV care, HIV PrEP or STI clinics without mpox diagnosis","restricted to sexually active persons aged 18-49 who self-identified as MSMS or transgender, excluding if first vaccine <= 14 days before index date","917",1127,309,608,NA,501,NA,NA,295,206,NA,NA,NA,416,NA,NA,"309","28",NA,NA,NA,NA,NA,NA,NA,NA,NA,"OR",95,"VE","2","Y","2 dose MVA-BN","N","0.85899999999999999","0.73799999999999999","0.92400000000000004",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"age, race, ethnicity, immunocompromising conditions and close contact with known mpox case, stratified by immunocompromised status and heterologous administration",NA,"Cases: 18-29 78 (25.2%),30-39 144 (46.6%), 40-49 87 (28.2%); controls 18-29 184 (30.3%), 30-39 87 (48.0%),  40-49 132 (21.7%)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"cases 94.2, control 89.5",NA,NA,NA,NA,NA,NA,NA,NA,NA,"30.1% cases, 47.9 % controls","32.4% cases, 23.4 controls","27.2 cases, 16.9 controls",NA,"48.1% cases PLW, 24.0% controls PLW",NA,NA,"21.4% cases, 20.4 % controls",NA,NA,"54.4% cases, 66.8% controls",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"40","37339074","Rosenberg","MMWR",2023,"Infection","none noted","Ryan White part B, Center for AIDS Research Supplement for Designing Differentiated PrEP Service Models for Implementation in New York City Emergency Departments, PrEP-ED Community Collaborative","Estimate vaccine effectiveness of full and partial vaccination","Case Control","MVA-BN","PEP, vaccination prior to exposure","1,2","both (data insufficient to calculate VE by route)","immunization registry","July 24 - Oct 31 2022","USA","Adult Male Mpox cases or adult male STI cases in New York state outside of New York City","Cases: males at birth 18 years of age or older with laboratory-confirmed mpox whose specimens were collected July 24-Oct 31 2022, control patients males at birth 18 years of age or older with rectal gonorrhea or primary syphilis over the same time frame with presumed sexual contact with male or transgender person","for primary syphilis ecluded if no male-to-male sexual contact","507",507,252,255,NA,73,NA,19,33,21,NA,NA,NA,434,NA,"1","252","22",NA,NA,10,10,2,"230",NA,NA,NA,"OR",95,"VE","2","N","2 dose MVA-BN","N","0.88500000000000001","0.441","0.97599999999999998",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"adjusted for diagnosis week, race, ethnicity, age, region in New York",NA,"case: 32.1 years (range = 18.5–66.4) ;  control: 31.3 (range 19.4–74.3)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"32.1 (range 18.5-66.4",NA,NA,"31.3 (range 19.4-74.3)",NA,NA,"all M cohort",NA,NA,"all MSM cohort",NA,NA,NA,NA,NA,NA,"69 case, 90 controls","106 cases, 40 controls","48 cases, 68 control",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"43","38218669","Rosen","Vaccine",2024,"Infection","none noted","NIH, Morris-Singer Fund, CDC","Determine PEP vaccine effectiveness of high-risk exposures","retrospective cohort with target trial emulation","MVA-BN","PEP","1","subcutaneous","immunization records and match or CIR (NYC Citywide Immunization Registry)","May 22- Aug 24, 2022","USA","18 years and older in NYC identified through DPH contact investigations to a case- patient with high or intermediate risk exposure to confirmed or probable  mpox with no vaccination or disease history prior to exposure","Receipt of 1st dose of MVA-BN <= 14 days after exposure and before symptom onset , case patient defined as individual who developed symptoms  <- 21 days after exposure with laboratory confirmation","missing symptom onset date and subsequently diagnosed with mpox, intradermal PEP, missing last exposure date, mpox disease on or prior to last exposure date, mpox vaccine given before last exposure date","594",594,NA,NA,NA,333,NA,333,NA,NA,333,NA,NA,261,NA,"1","39","10",NA,NA,10,NA,NA,"29",NA,NA,NA,"OR",95,"VE","1","Y","1 dose MVA-BN PEP < 14 days after last exposure (method 1: multivariable regression)","N","0.78","0.5","0.91",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"14< days after last exposure","35","range 18-87",NA,NA,NA,NA,NA,"35 (range 19-76)",NA,NA,"35 (range 18-87)",NA,NA,NA,NA,NA,NA,NA,NA,NA,"454","269",185,NA,NA,NA,NA,NA,NA,NA,"214","178","122",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwip8pah09T-AhX-EVkFHauWCkEQFnoECAsQAQ&url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Facip%2Fmeetings%2Fdownloads%2Fslides-2023-02%2Fslides-02-22%2Fmpox-04-chard-508.pdf&usg=AOvVaw1lFnLLjVVxLSUYO85YIdNp"
"45","36580416","Farrar","MMWR",2022,"Severity","CDC","not noted","To assess differences in illness among vaccinated and unvaccinated persons with mpox","Cross Sectional","MVA-BN","PEP, vaccination prior to exposure","1","Subcutaneous and intradermal",NA,"May 22 - Sept 3 2022","USA","US population at risk for mpox"," Probable and confirmed mpox cases among persons with illness onset during May 22–September 3, 2022, in the 29 jurisdictions, vaccination >= 14 days before illness onset","1) No vaccination date or vaccination status available 2) receipt of vaccine before may 2022, 3) illness <= 13 days after vaccine dose","6605",6605,NA,NA,NA,276,NA,NA,NA,NA,NA,NA,NA,6329,NA,"1","6605","276",NA,NA,NA,NA,NA,"6329",NA,NA,NA,"OR",95,"VE","1","N","MVA-BN Fever","N","0.56000000000000005","0.4","0.67999999999999994",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,55,198,"2451",5266,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,">=14 days after MVA-BN vaccine","36 vaccinated, 34 unvaccinated",NA,NA,NA,NA,NA,"34",NA,"35.299999999999997",NA,"36.9",NA,"36.9",NA,NA,NA,NA,NA,NA,NA,"6203, (402 missing)","259",5710,NA,NA,NA,NA,NA,NA,NA,NA,"64 vaccinated, 1,880 unvaccinated, 177 missing","33 vaccinated, 1,901 unvaccinated, 199 missing",NA,NA,"19/78, 137 unknown","1074/2585, 3,099 unknown",NA,NA,NA,NA,NA,NA,"3237","2/95 vaccinated, 237.3,142 unvaccinated",NA,NA,NA,NA,NA,NA,NA
"77","36874154","Hens","New Microbes Infection",2023,"Severity","Research Foundation Flanders","none stated","Describe characteristics of mpox cases in Belgian sexual health clinic","case-control","Historic smallpox vaccine, MVA-BN","PEP, vaccination prior to exposure",NA,"Subcutaneous","standardized electronic form","May 23-Sept 20, 2022","Belgium","patients of sexual health clinic seeking care for mpox","positive in-house PCR testing for cases, negative testing for controls","not stated","155",155,NA,NA,NA,40,33,5,2,NA,NA,NA,NA,136,25,"1","155","28",25,NA,1,2,NA,"102",NA,NA,"of unvaccinated mpox cases, 25 unknown vaccine status,  (25 historic, 1 PEP, 2 PrEP)","multivariable Beta",95,"VE","1","Y","Smallpox Childhood - CT PCR anorectal swab","N","3.0000000000000027E-2","-0.16666666666666663","0.21999999999999997","0.97","0.78","1.2",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"39 39 (IQR 33-46) mpox positive, 37 ( 31.0-46) mpox negative",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"39","33",46,NA,NA,NA,"204 (99%)",NA,NA,"187 (90.8%), 144 (92.9%) mpox positive, 84.3% mpox negative",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"53 ( 34.2%) mpox positive, 13 (25.5%)  mpox negative, 10 unknown in mpox positive, 5 unknown mpox negative,",NA,NA,NA,NA,NA,"of 93 negative mpox cases, 22 not using PrEP, 63 using PrEP, 8 unknown; of 33 HIV negative mpox negative, 9 not using PrEP, 21 using PrEP, 3 unknown",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"151","36787016","Kroger","Infection",2023,"Severity","none","none","evaluate clinical epidemiologic characteristics of mpox in Cologne, Germany","Retrospective cohort","Historic smallpox vaccine, MVA-BN","PEP, vaccination prior to exposure",NA,NA,"detailed structural interview","May 24,2022- Oct 30 2022","Germany","persons with confirmed mpox detected by health department","PCR confirmed positive mpox infection","did not respond to questions or lived outside of Cologne and not followed by the health department","393",368,NA,NA,NA,129,96,19,14,NA,NA,NA,NA,239,NA,"1","368","129",96,NA,19,14,NA,"239",NA,NA,"6 both smallpox and MVA-BN, assumed to be PrEP","OR",95,"VE","NA","Y","Any vaccine hospitalized","N","0.77","-0.46524064171123003","0.97","0.23","0.03","1.87",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"HIV status and age",NA,"range 12-80",NA,NA,"41","10",NA,NA,NA,NA,NA,NA,NA,NA,NA,"mean 41, sd 10",NA,NA,NA,NA,NA,"367","33 with childhood smallpox, 19 MVA-BN PEP, 14 with PrEP",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"143",NA,NA,NA,NA,NA,NA,NA,NA,"368","13",NA,NA,NA,NA,NA,NA,NA
"Descriptive","36695469","Merad","Eurosurveillance",2022,"Infection","None noted","None","provide data on breakthrough mpox and investigate limitations of MVA-BN PEP","Cohort","MVA-BN","PEP","1","not specified","self-report","June 15-Aug 12, 2022","France","adults (18 years old) seeking MVA-BN vaccination at hospital","Consecutive adults 18 and older who received MVA-BN PEP with mpox exposure 14 days  or less after PEP","mpox symptoms before vaccination, time from contact to vaccination> 14 days, missing data, withdrew consent","130",108,NA,NA,NA,108,25,108,NA,NA,NA,NA,NA,NA,NA,"1","11","11",1,NA,11,NA,NA,NA,NA,NA,NA,"OR",95,"VE","1","N","MVA-BN PEP cycle threshold viral culture","N",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"35","29","44",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"34","28",36,NA,NA,NA,"97",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"15","15","3","12",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"171","36201401","Payne (a)","MMWR",2022,"Infection","none","none","Examine the incidence of monkeypox among persons who were unvaccinated and those who had received ≥1 JYNNEOS vaccine dose,","Retrospective cohort","MVA-BN","Vaccination prior to exposure","1,2","subcutaneous and intradermal","patient interview or link cases with vaccination data","July 31–Sept 3, 2022","USA","men 18-49 either MSM living with HIV acquired through male sexual contact and or injection drug use or eligible for HIV-PrEP","aggregate weekly numbers of confirmed and probable mpox cases ages 18-49 in 32 jurisdictions","smallpox vaccination in childhood (excluded by age)","5402",5402,NA,NA,NA,796,NA,NA,NA,NA,NA,NA,NA,4606,NA,"1","5404","796",NA,NA,69,142,12,"4606",NA,NA,"(450 with unknown vaccination date, 346 with known vaccination date, 269 illness within 0-13 days after first day, 77 >= 14 days after first dose, 65 before second dose, 10 0-13 after 2nd dose, 2 >= 14 after second dose)","IRR",95,"VE","1","Y","1 dose MVA-BN","N","0.93006993006993011","0.8","0.97560975609756095","6.9930069930069921E-2","2.4390243902439025E-2","0.2",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"week of case",">= 14 days after first vaccine","cohort of 18-48",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"5402",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"174","36480479","Payne (b)","MMWR",2022,"Infection","CDC","none","Quantify move-bn vaccine effectiveness 1 and 2 doses  against mpox infection","cross-sectional study, surveillance","MVA-BN","Vaccination prior to exposure","1,2","subcutaneous and intradermal","immunization registry and interviews, The total number of persons vaccinated as of 2 weeks before the end date of a week divided by the estimated vaccine-eligible population aged 18–49 years","July 31- Oct 1 2022","USA","men 18-49 either MSM living with HIV acquired through male sexual contact and or injection drug use or eligible for HIV-PrEP","aggregate weekly numbers of confirmed and probable mpox cases ages 18-49 in 43 jurisdictions with illness onset July 31 to September 3, 2022","incomplete records (possible vaccinated but without dose number or dose date) and vccinated before 2022","11581",9544,NA,NA,NA,1124,NA,NA,NA,NA,NA,NA,NA,8320,NA,"1","9544","1224",NA,NA,614,687,97,"8320",NA,NA,"(inc. 218 unknown vaccine date,. 614 0-13 days after dose 1, 392 >= 14 days after dose 1, 295 before dose 2, 49 0-13 days after dose 2, 48 >= 14 days after dose 2)","IRR",95,"VE","1","Y","1 dose MVA-BN","N","0.86486486486486491","0.83333333333333337","0.89010989010989006","0.13513513513513511","0.10989010989010989","0.16666666666666666",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"week of case",">= 14 days after first vaccine","cohort of 18-49",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"9544","1224",8320,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Linkage of mpox case surveillance and vaccination administration data might have resulted in misclassifications (report assumes that persons with unknown vaccination status were unvaccinated); could not control for differences in testing/behaviors that affect risk for virus exposure or possible differences in risk of infection because of patient characteristics; temporality of exposures that result in infection is now known; confirmation that all identified persons with mpox were members of population eligible for vaccination were not possible; considering persons vaccinated as of 2 weeks before end date of surveillance week could overestimate number of persons vaccinated each week",NA,NA
"491","36477495","Thy","NEJM",2022,"Infection","none","none","describe the outcomes of high-risk contacts receiving third-generation smallpox vaccine as an early postexposure ring vaccination (EPRV) especially tolerance and potential breakthrough infections after the first dose.","Prospective cohort","Historic smallpox vaccine, MVA-BN","PEP","1","Subcutaneous","vaccine given","May 27 - July 13, 2022","France","high risk mpox exposure, France","consecutive patients of 3rd gen MVA-BN after high risk exposure",NA,"276",276,NA,NA,NA,276,30,276,NA,NA,276,NA,NA,0,NA,"1","12","12",30,NA,276,NA,NA,"0",NA,NA,NA,"OR",96,"VE","2","N","MVA-BN PEP","N","-0.71729187098218739","-0.91786042844000526","0.12949840000000001","3.5372170000000001","0.87050159999999999","12.1744",NA,NA,NA,NA,NA,NA,NA,4,12,"33",264,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"19","14","25",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"24","15.8",26.8,NA,NA,NA,"250","250",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"38","38","0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"195","36082686","Vaughan","Eurosurveillance",2022,"Severity","ECDC","none","describe epidemiology of MPX and severity based on  prior vaccination in all cases on WHO European region","Retrospective cohort","Historic smallpox vaccine, MVA-BN","Vaccination prior to exposure, PEP",NA,"unclear","unclear (reported to TESSYy)","March 7 - Aug 23, 2022","European region",NA,"reported to TESSY as MPOX cases","none stated","20960",3502,NA,NA,NA,575,528,46,5,NA,NA,NA,NA,17458,NA,"1","3502","528",NA,NA,NA,NA,NA,"2974",NA,NA,"(table 3 for prior smallpox) , 528 before outbreak, 1 PrEP, 42 PEP++, 4 PrEP/PEP++, vaccination 3017+2974 for prior to event","Firth logistic regression, OR,",NA,"VE","1","Y","Any vaccine hospitalized","N","-6.5420560747663559E-2","-0.49238578680203049","0.47","1.07","0.53","1.97",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"age and hospitalization",NA,"37","31","44",NA,NA,"vaccination broken down by age bracket, 0-17 0 vaccinated, 10 unvaccinated, 18-30 49 vaccinated, 817 unvaccinated, 31-40 94 vaccinated 1,298 unvaccinated,  41-50 130 vaccinated, 680 unvaccinated, 51-60 189 vacciant3d, 132 unvaccinated, >60 62 vaccinated, 27 unvaccinated. all adjusted OR not significant",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"17685/17896",NA,NA,"8771/9053",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"3070/8257",NA,NA,NA,NA,NA,NA,NA,NA,"3359 (143 unknown)","106","12","94","495","2758",NA,NA,NA
"223","36720271","Wolff-Sagy","Nature Medicine",2023,"Infection","none","none","assess the effectiveness of providing one dose of the mva-bn vaccine in a real-world at-risk population as assess by laboratory confirmed RT-PCR tests","Retrospective cohort","MVA-BN","Vaccination prior to exposure, PEP","1","Subcutaneous","from electronic medical record of CHS (Clalit Health Services), largest of the integrated health organizations in Israel","July 31- Dec 25, 2022","Israel","Men 18-42 eligible for mpox vaccination at large integrated healthcare organization, Israel","males ages 18-42 who were either given HIV-PrEP for at least 1 month since 1 January 2022 or diagnosed with HIV and one or more STIs since 1 January 2022","Infection with mpox prior to study period","2054",2054,NA,NA,NA,1037,NA,NA,1037,NA,1037,NA,NA,1017,NA,"1","21","5",NA,NA,NA,NA,NA,"16",NA,NA,NA,"HR (univariate and multivariate)",95,"HR","1","Y","1 dose MVA-BN","N","0.86","0.59000000000000008","0.95","0.14000000000000001","0.05","0.41",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Tel Aviv district, Chlamydia or Ne gonorrhea recent urine PCR, recent syphilis infection","minimum of 90 days of follow up",NA,NA,NA,"33.799999999999997","5.4",NA,NA,NA,"33.5","5.8",NA,NA,"34.1","4.9000000000000004",NA,NA,NA,NA,NA,NA,"2054","1037",1017,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"647 (31.5%)","136 (13.1%)","551 (50.2%)",NA,NA,NA,"1382","876","506",NA,NA,NA,NA,NA,NA,NA,NA,"(listed as Zucker in COVIDNECE, was Arbel pre-print),"
"227","NA","Ghosn","CROI conference abstract https://www.croiconference.org/abstract/impact-of-vaccination-on-mpox-incidence-in-msm-on-prep-in-the-anrs-174-doxyvac-trial/",2023,"Infection","unknown","unknown","impact of MVA-BN vacation on MSM on PrEP and smallpox childhood vaccination participating in a clinical trial","Randomized control trial with nested case control and prospective cohort","Historic smallpox vaccine, MVA-BN","Vaccination prior to exposure, PEP","not stated","not clear","unclear","May 9 - Sept 20, 2022","France","MSM on PrEP with STI in past year clinical trial","unclear","unclear","546",472,NA,NA,NA,94,NA,NA,NA,NA,NA,NA,NA,NA,NA,"1","77",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"IRR",95,"VE","1","Y","Smallpox Childhood","N","0.13900000000000001","-0.65229485396383868","0.74199999999999999","0.86099999999999999","0.25800000000000001","2.8759999999999999",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"39",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"small sample size, lack of data for all 546 participants.",NA,NA
"Descriptive","37044128","Faherty","EID",2023,"Infection","none noted","none noted","describe persons with mpox who attended market Days festival in Chicago, Illinois USA Aug 6-7 2022","prospective and retrospective cohort","MVA-BN","PEP, vaccination prior to exposure","1","presumably Subcutaneous","interview","July 16-Aug 28, 2022","USA","Attendees of Chicago Market days 2022","attendance of MD by mpox case-patient",NA,"40",40,NA,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,25,NA,"1","40","15",NA,NA,NA,NA,NA,"25",NA,NA,NA,NA,NA,NA,NA,NA,"MVA-BN descriptive behavior",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"symptoms 21 days before or after MD days","31","27.3","35.799999999999997",NA,NA,"32 (29-35.5)","30 (25.5-35.5)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"39","15",24,"28","11","17",NA,NA,NA,NA,"18 (8 vaccinated, 10 unvaccinated)","13 ( 5 vaccinated, 8 unvaccinated)","9 (2 unvaccinated, 7 vaccinated)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Descriptive","36178700","Hazra","JAMA",2022,"Severity","none noted","none","describe mpox infections after single dose of MVA-BN among largest mpox testing and vaccination site in the US-Midwest","Retrospective cohort","MVA-BN","Vaccination prior to exposure, PEP","1","not stated, Subcutaneous and intradermal  presumably based on timing",NA,"June 28 - Sep 9, 2022","USA","US Midwest patients who received 1 dose of MVA-BN and tested positive for mpox","patients who tested positive for mpox at least 1 day after first dose of MVA-BN from June 28, 2022 to September 9 2022","none","90",90,NA,NA,NA,90,NA,NA,90,NA,NA,NA,NA,0,NA,"1","90","90",NA,NA,NA,90,NA,NA,NA,NA,NA,"N/A",NA,NA,NA,NA,"MVA-BN timing",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"33","29","41",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"82","82",NA,NA,NA,NA,NA,NA,NA,NA,"33","24","19","90 (assumed)","34","34","0","0",9,NA,"32","32","0",NA,NA,NA,NA,NA,NA,"small sample size, single site, postvaccination observation period was not uniform throughout the cohort",NA,NA
"230","37120092","Jamard","Infectious Diseases Now",2023,"Severity","none","none","describe case of mpox after January 27 2023 in Loire, France","Outbreak Investigation","MVA-BN","Vaccination prior to exposure","1,2","subcutaneous and intradermal",NA,"Jan  – March 2023","France","at risk for mpox in Loire valley, France","confirmed PCR + mpox at University of Tours, France",NA,"15",15,NA,NA,NA,9,NA,NA,NA,NA,NA,NA,NA,6,NA,"1","15","9",5,NA,NA,9,NA,"6",NA,NA,"(9 with MVA-BN, of these 5/9 also received first generation vaccine before 1984)","OR",95,"VE",NA,"N","Any vaccine - Rash","N","NA","NA","NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,9,"6",6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"40","33.5","49.5",NA,NA,"48 (36-51)","35.5 (32.5-40.75)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"all cases associated with confirmed mpox cases or unsafe sex with multiple partners","9",6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"4","1","3","0",NA,NA,"10","7 of 8","3 of 3",NA,NA,NA,NA,NA,NA,NA,NA,"Facial rash and oropharyngeal rash lumped together, just put under facial rash here, trunk and limbs lumped together put under trunk here"
"239","36992376","Candela","Viruses",2023,"Severity","none","none","describe demographical data, symptoms presentation and clinical course until outcome of individuals diagnosed with mpox, from May to October 2022, in IRCCS San Raffaele Hospital in Milan, Italy","Retrospective cohort","Historic smallpox vaccine, MVA-BN","Vaccination prior to exposure, PEP",NA,"not noted","unclear","May 25, 2022- Oct 10, 2022","Italy","People who accessed Sexual Health Clinic in IRCCs San Raffaele Hospital, Milan Italy between May and October 2022","Positive by RT-PCR","not listed","140",140,NA,NA,NA,23,20,NA,1,NA,NA,NA,NA,120,NA,"1","140","20",NA,NA,NA,NA,NA,"120",NA,NA,NA,"OR",95,"VE","NA","N","Any vaccine hospitalized","N","-7.4213000000000084E-2","-0.86601595080105709","0.96081293000000001","1.0742130000000001","3.9187069999999997E-2","7.4635749999999996",NA,NA,NA,NA,NA,NA,NA,1,23,"5",112,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"none",NA,"37","33","43",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"137",NA,NA,"134",NA,NA,"22","1",NA,NA,NA,NA,NA,NA,"66",NA,NA,NA,NA,NA,"43",NA,NA,NA,NA,"1 (unclear if Dryvax vs MVA-BN)","5","22","112",NA,NA,NA
"241","37783731","Agustí","Nature Communications",2023,"Infection","Ministry of Health of Government of Catalonia (Spain), Grifols,
Pharma Mar, HIPRA, Amassence and Palobiofarm","none","(i) assess the prevalence of MPXV infection among highly exposed GBMSM and trans women asymptomatic or with mild unrecognized Mpox symptoms, who were recruited in a community-based center in Barcelona, (ii) to assess the presence of replication-competent particles of MPXV and (iii) to evaluate the feasibility and acceptability of a community-based self sampling strategy for Mpox diagnosis.","Cohort study","Historic smallpox vaccine, MVA-BN","Vaccination prior to exposure",NA,NA,"self-report","Aug-Oct 2022","Spain","GBMSM and TW at HIV community center in Spain","GBMSM or TW, over 18 years old, no symptoms of MPXV infection and considered high risk of contracting Mpox (High risk was defined as: GBMSM and TW who are sex workers and/or chemsex users and/or who practice group ex and/or are HIV positive or are PrEP users.)","none","113",113,7,NA,NA,13,NA,NA,NA,NA,NA,NA,NA,75,NA,"1","20","1",7,NA,13,NA,NA,"4",NA,75,NA,"OR",95,"VE",NA,"N","Smallpox Childhood",NA,"1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,7,"4",75,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"35","30","43",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"89",NA,NA,"84",NA,NA,NA,NA,NA,NA,NA,NA,NA,"105","44",NA,NA,NA,NA,NA,"41",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"243","37676838","Schildhauer","MMWR",2023,"Severity","None noted","U.S. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, Board of Directors National Alliance for State and territorial AIDS Directors","determine risk of mpox-associated hospitalization by MVA-BN status","Retrospective cohort","MVA-BN","Vaccination prior to exposure, PEP","1,2","unclear","interview","May 12, 2022- May 18, 2023","USA","California residents at risk for mpox","California residents with laboratory confirmed mpox with hospital information","hospitalization status missing or unknown,","5765",4611,4611,NA,NA,769,NA,457,233,79,NA,NA,NA,3845,NA,"1","4614","769",NA,NA,NA,NA,NA,"3845",NA,NA,NA,"OR",95,"VE","1","N","MVA-BN 1 dose hospitalized","N","0.73","0.35","0.92","0.27","0.08","0.65",NA,NA,NA,NA,NA,NA,NA,4,230,"233",3845,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"35 (25-48)",NA,NA,NA,NA,"1 dose 35 (22-48), 2 doses 36 (24,5-47.5), PEP 38 (24-52","35 (21-49)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"4,353 ","223 1 dose, 77 2 dose, 443 PEP, 3,610 unvaccinated",3610,"3188","189 1 dose, 69 2 dose, 375 PEP,","2555",NA,NA,NA,NA,"1329","2083","590","4611","1878","81 1 dose, 19 2 doses, 193 PEP","1585",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"252","37678309","Hazra","Lancet Infectious Diseases",2024,"Severity","None","None","describe demographics of breakthrough vaccine cases or after prior infection","Case series","MVA-BN","Vaccination prior to exposure","2","subcutaneous or intradermal ( 14.30 2x subcutaneous, 8 subcutaneous/ID, 8 ID, ID)","Electronic health record","May 11 - Jan 30, 2022","International","at risk for mpox in 2022 outbreak","confirmed case of mpox after past infection by PCR positive, or confirmed case PCR positive from any anatomic site 14 days after 2 doses of vaccination","could not confirm vaccination status, partial immunization or received doses before May 1, 2022","37",37,30,8,NA,30,NA,NA,NA,NA,NA,NA,NA,8,NA,"1","37","30",NA,NA,NA,NA,NA,"8",NA,NA,NA,NA,95,"VE","2","N","MVA-BN vesicuo pustular",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,30,"3",8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"36","30","34",NA,NA,"37 (30-45)","35 ( 31-37)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"37","30",8,"36","29","8",NA,NA,NA,NA,"28 (5 prior infection, 24 vaccination)","4 (3 prior infection, 1 vaccination)","2 (2 prior vaccination)",NA,"8","3","5","median most recent CD5 555 (IQ 363-979) overall, 452 (296-852 unvaccinated) and 925 (662-1244) vaccinated",NA,"8","24","22","3",NA,NA,NA,NA,NA,NA,NA,NA,NA
"271","37769158","Brousseau","Clinical Infectious Diseases",2023,"Infection, Severity","Ministere de la Sante et des Services sociaux du Quebec","No","estimate VE of subcutaneous single-dose MVA-BN against symptomatic mpox including moderate to severe disease","Test negative case-control","MVA-BN","Vaccination prior to exposure","1","Subcutaneous","Several administrative and surveillance databases inc. mpox provincial immunization registry linked by Quebec unique health insurance number","Jun 19-Sept 24 2022","Canada","men over 18 high risk for mpox in Montreal","over 18 years old, specimens in high area of mpox in Montreal","women, positive before study period, specimens from non-skin lesions, asymptomatic, living outside the province, received 1 MVA-BN dose <14 days or 2doses at any time before specimen collection.","532",532,231,301,NA,161,NA,NA,NA,NA,NA,NA,NA,371,NA,"1","231","59",NA,NA,NA,NA,NA,"172",102,199,NA,"OR",95,"VE","1","Y","MVA-BN 1 dose Infection All-Admin","N","0.35","-0.02","0.59",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"age, calendar time, STI tests and diagnosis, HIV status",NA,"broken in 18-29, 30-49, >=51",NA,NA,NA,NA,"Cases: 18-29 50, 30-49 143, >=51 38;  Contro: 18-29 90, 30-49 146, >=51 65;",NA,NA,NA,NA,NA,NA,NA,NA,"22% 18-29, 62% 30-49, 16%>=50",NA,NA,"30% 18-29, 49% 30-49, >=50 16%",NA,NA,"523",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NA",NA,NA,NA,NA,NA,NA,NA,NA,NA,"231","3","(1 ""moderate to severe vaccinated)","(11""moderate to severe unvaccinated"")",NA,NA,NA,NA,NA
"279","37318762","Morales","Eurosurveillance",2023,"Infection","None noted","None","assess PEP VE in early 2022 outbreak","Dynamic prospective cohort","MVA-BN","PEP","1","Subcutaneous","Administer MVA-BN in clinic after epidemiologic investigation of contacts of known cases","May - Aug 2022","Spain","contacts of known mpox cases in Spain, early 2022","Close contacts of known confirmed symptomatic mpox cases via contact with body fluids or lesions, contacted fomites or clinical samples without PPE a","index case could not be laboratory confirmed, contact with compatible mpox symptoms and etiology could not be confirmed, date of risk of contact not established or risk of exposure during follow up outside the home","491",484,NA,NA,NA,230,NA,NA,NA,NA,NA,NA,NA,254,NA,"1","57","8",NA,NA,NA,NA,NA,"49",NA,NA,NA,"HR",95,"VE","1","Y","1 dose MVA-BN PEP","N","0.88800000000000001","0.76","0.94699999999999995",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6099,8,5774,49,0.844,".664-.928",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"35 (31-40)","34 (30-38)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"7","40",NA,NA,NA,NA,NA,NA,"25","4","21",NA,NA,NA,"10 (0 vaccinated, 10 unvaccinated)",NA,NA,NA,"1","0","1",NA,NA,NA,NA,NA
"314","37347713","Faherty","MMWR",2023,"Severity","None noted","Water Environment Federation","determine cluster of vaccinated cases of mpox scope and commonalities of MVA-BN vaccine",NA,"2 doses MVA-BN,1 dose ACAM200","vaccination prior to exposure","1 or 2","Subcutaneous or intradermal","not stated","March 18-June 12 , 2023","USA","cases reported during time periods to Chicago DPH","laboratory confirmed mpox case in Chicago","none","40",40,NA,NA,NA,22,NA,NA,NA,1,8,1,7,18,NA,"1","40","22",NA,1,NA,NA,16,"18",NA,NA,"vaccinated defined as 2 dose MVA-Bn or ACAM 2000, unvaccinated 1 dose or none",NA,NA,NA,NA,"N","MVA-BN 2 doses/ACAM 2000 vs MVA-BN 1 dose or no vaccine affecting genitals","N",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1.32,22,"7.74",18,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"34 (31-40)",NA,NA,NA,NA,"30.5","(28-38)",NA,NA,NA,NA,NA,NA,NA,NA,"37","20",17,NA,NA,NA,NA,NA,NA,NA,"19 (13 vaccinated, 6 under vaccinated)","8 (4 and 4)","7 (1 and 6)",NA,"11","5","6",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"317","37864849","Fontán-Vela","Clinical Infectious Diseases",2023,"Infection","None noted","1 author expert testimony for Moderna and GSK, meetings/travel Pfizer and MSD","estimate reduction of risk of MPXV infection associated with at least 1 dose of MVA-BN pre-exposer in persons receiving HIV-PrEP","retrospective cohort with target trial design","MVA-BN","vaccination prior to exposure","1","subcutaneous  or intradermal ( 3502 or 61.9% intradermal, 1707 or 30.2 subcutaneous, 451 or 7.9% unknown)","linked records","July 12 - Dec 12, 2022","Spain","on HIV-PrEP in Spain","on HIV-PrEP in national database older than 18","started HIV-PrEP before including in NHS (Nov 2019), missing date of mpox infection of >= 3 doses of MVA-BN","10449",10449,5660,NA,NA,5660,NA,NA,NA,NA,NA,NA,NA,5660,NA,"1","43","18",NA,NA,NA,NA,NA,"25",18,25,"5660 (3,899 unique individual)","RR",95,"VE","1","N","1 dose MVA-BN overall","N","0.379","-0.24399999999999999","0.69099999999999995","0.62","0.31","1.24",NA,NA,NA,NA,NA,NA,NA,18,NA,"25",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"18-29 17.4%, 30-39 46.2%, 40-49 27.3%, >=50 9.1%",NA,NA,NA,NA,"18-29 17.7%, 30-39 46.4%, 40-49 27.5%, >=50 9.1%",NA,NA,NA,NA,"18-29 17.7%, 30-39 46.1%, 40-49 27.1%, >=50 9.1%",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"332","37590262","Eustaquio","MMWR",2023,"Severity","None noted","None","describe age-group specific epidemiologic characteristics and outcomes in adults aged >50 yo by recent MVA-BN in the US","retrospective cohort","MVA-BN","not stated",">=1","Subcutaneous or intradermal","NHDSS or standardized case report form","May 10, 2022 - May 17 ,2023","USA","risk for mpox in US 2022 outbreak","confirmed or probable mpox cases persons >= 18",NA,"29984",29984,29984,NA,NA,2763,NA,NA,NA,NA,NA,NA,NA,9915,NA,"1","1020","282",NA,NA,NA,NA,NA,"738",NA,NA,"( 2,481 18-50, 282 >50, 15,417 missing 18-50, 1,889 missing >50) total vaccinated,  ( 9,177 18-50, 738 >50) total unvaccinated, 1020 cases included in final analysis","OR",95,"VE",">=1","N","MVA-BN HIV status >50 years old","N","0.18999999999999995","-0.19999999999999996","0.48","0.81","0.52","1.25",NA,NA,NA,NA,NA,NA,NA,60,97,"492",737,81,2075,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"2,909 (9.7%) were >50, 27,075 18-50 yo",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"25,681 cis men 18-50, 2,794 cis men > 50",NA,NA,"12,561 18050, 1,393 >50 yo, 419 cis men and other 18-50 yo, 32 >50 cis and other",NA,NA,NA,NA,NA,NA,"7,085 18-50 yo, 1,297 >50","7,878 age 18-50, 758 >50","8,733 18-50, 561 >50",NA,"4,798 18-50 positive, 522 >50 positive; 3,860 18-50 negative, 282 >50 negative, 18,417 18-50 unknown, 2,075 >50 unknown",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"340","37942460","Ramchandani","OFID",2023,"Infection","All of the National Institutes of Health","unrelated support from Hologic, consultant Roche, honoraria Providence Health, IDSA, Nabriva","determine vaccine effectiveness of MVA-BN","retrospective cohort","MVA-BN","nt Pre-exposure vaccination","1 or 2","subcutaneous  or intradermal","Secure medical record matched to Washington State Immunization Information System (WAIIS)","May 1 - Dec 21, 2022","USA","attend sexual health clinic in Seattle","Public Health-Seattle and King County patients  (PHSKC) patients who resided in King County and had 1 clinic visit between 1 Jan 2020 and 31 Dec 2022, assigned male at birth and reported sex with men","none noted","4230",4230,204,NA,NA,1837,NA,NA,686,1152,NA,NA,NA,2393,NA,"1","203","13",NA,NA,NA,11,2,"191",NA,NA,"685 1 dose (216 subQ, 469 ID), 1152 2 doses (36 subcutaneous, 434 ID, 682 heterologous) for mpox cases,  (11 1 dose (4 subQ, 7 ID,","HR",95,"VE","1","Y","1 dose MVA-BN","N","0.81","0.64","0.9","0.19","0.1","0.36",NA,NA,NA,NA,NA,NA,NA,11,685,"191",2393,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"34",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"4230",NA,NA,NA,NA,NA,NA,NA,NA,NA,"2569","768","451","3715","630 (515 unknown)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"342","37838481","van Ewijk","Vaccine",2023,"Infection","Ministry of Health, Welfare and Sports","None","characteristics of high-risk contacts exposures to a confirmed mpox cases, PEP uptake, timing and mpox symptom development","retrospective observational cohort of high-risk mpox contacts","MVA-BN","PEP","1","not stated","Hpzone database","May 20 - July 22, 2022","Belgium","high-risk contact of confirmed mpox index case in Belgium","high-risk contact","low or medium risk contact","264",264,38,NA,8,233,28,233,NA,NA,NA,NA,NA,41,24,"1","38","16",NA,NA,NA,NA,NA,"2",NA,NA,"108 active follow up, 174 passive follow up, 8 lost to follow-up, 7 probable, 31 confirmed cases","SAR",95,"VE","1","N","MVA-BN PEP all high risk contact","N","-0.28299999999999997","-0.82817870000000005","0.67",NA,NA,NA,NA,NA,NA,"16",2,"218",38,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"36 (range 8-72)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"217 of 287",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"351","37373818","Estevez","Journal of Clinical Medicine",2023,"Severity","None","none","main epidemiologic and clinical findings of mpox in nonendemic countries of suspected and confirmed cases","Cohort study","MVA-BN","not stated","not stated","not stated","unclear","May 18 - Sep 30, 2022","Spain","at risk for mpox","suspected, probable and confirmed mpox",NA,"133",133,100,NA,NA,15,NA,NA,NA,NA,NA,NA,NA,66,NA,"1","100","15",NA,NA,NA,NA,NA,"66",NA,NA,NA,"OR",NA,"Descriptive",NA,NA,"MVA-BN days between onset of symptoms and skin lesions",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2.2,7,1.7,3.5,NA,NA,NA,NA,NA,NA,NA,NA,"33","30","42",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"97",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"99","71",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"401","37017138","Garcia-Hernandez","Revista espanola de salud publica",2023,"Severity","none noted","none noted","describe epidemiologic features of mpox in the Canary Islands","retrospective cohort","Historic smallpox vaccine and 3rd gen","not stated","not stated","not stated","unclear","May 19 - Dec 31, 2022","Canary Islands","at risk for mpox in Canary islands","PCR positive mpox","none noted","177",NA,NA,NA,NA,38,37,NA,1,NA,NA,NA,NA,138,NA,"1","177","38",NA,NA,NA,NA,NA,"1",NA,NA,"unclear timing of 1 current MVA-BN","OR",95,"VE",NA,NA,"Any vaccine- bacterial secondary infection",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,38,"3",138,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"39","32.799999999999997","48.3",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"82",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"403","37516243","Higgins","Am J of transplantation",2023,"Severity","none","none","describe course and outcomes of mpox infection in solid organ transplant recipients","case series","Historic smallpox vaccine, MVA-BN","not stated","not stated","not stated","unclear","July 2022 - Feb 2023","USA","solid organ transplant recipients at risk for mpox","SOT recipient over 18","none noted","11",11,11,NA,NA,3,2,NA,1,NA,NA,NA,NA,8,NA,"1","11","3",NA,NA,NA,NA,NA,"8",NA,NA,NA,"OR",95,"VE",NA,NA,"Any vaccine - hospitalization SOT patients","N","0.69696970000000003","0.50909090000000001","0.79924930000000005","0.30303029999999997","0.2007507","0.49090909999999999",NA,NA,NA,NA,NA,NA,NA,1,3,"6",8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"37","23","53",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"11",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"3","8",NA,"7",NA,NA,"(median CD4 632, range 267-1487)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Descriptive","37819966","Arbel","NEJM",2023,"Infection","none","none","Re-run analysis of prior publication","Re-run analysis","MVA-BN","MVA-BN","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"MVA-BN descriptive",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"477","37616117","Morales","Eurosurveillance",2023,"Infection",NA,NA,NA,"Re-run analysis","MVA-BN","MVA-BN","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,95,"VE",NA,"Y","MVA-BN PEP ITT including patients not vaccinated 2/2 symptoms as vaccinated","Y","0.746","0.55400000000000005","0.85499999999999998",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
